• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Paranovus Entertainment Technology Ltd Signs Letter Of Intent To Acquire BlueLine Studios, Pivoting To AI-Entertainment For ~$3.2M In Cash And Unregistered Class A Ordinary Shares

    9/6/23 8:36:47 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email

     Expansion into AI-powered online entertainment industry reflects strategic evolution of the business model

    NANPING, China, Sept. 6, 2023 /PRNewswire/ -- Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS) (the "Company") today announced that it has signed a non-binding Letter of Intent (LOI) to acquire 100% of BlueLine Studios Inc. ("BlueLine"), a portfolio company of Caravan Digital L.P. ("Caravan"), a co-founder of consumer companies authentically powered by iconic artists and athletes in partnership with Creative Artists Agency ("CAA").

    The deal is anticipated to close in the fourth quarter of 2023, provided that the parties reach a definitive agreement and the Company secures financing of at least $5 million. The completion of the deal is subject to customary approvals and closing conditions, including but not limited to satisfactory completion of due diligence and the Company's receipt of the payoff letters pertaining to certain indebtedness of BlueLine. 

    Under the terms of the LOI, PAVS would acquire 100% of BlueLine's equity interests from Caravan and other equity owners of BlueLine. The consideration to be paid by the Company to purchase the equity interests is approximately $3.2 million in cash and unregistered Class A ordinary shares. Additionally, the Company will issue $1.11 million worth of its unregistered Class A ordinary shares to Caravan. Furthermore, the Company will issue $3.6 million worth of its unregistered Class A ordinary shares and $2.0 million worth of restricted stock units to a special purpose vehicle ("SPV") controlled by Mike Teh Wang, who represents BlueLine management. Finally, the Company will make a payment of $1.63 million in cash and unregistered Class A ordinary shares to the financial advisor for this Acquistion at the closing.

    Based in Vancouver, BlueLine is a video game developer that builds engaging interactive gaming experiences powered by world-class celebrity talent. BlueLine's portfolio of games includes a previously released match-3 mobile game, Apple Arcade's first trivia game, and other strategic projects in development.

    Before joining BlueLine, its team had amassed extensive experience in the gaming industry. Their track record includes participating in the development of multiple AAA titles, such as numerous Need For Speed and EA Sports games at Electronic Arts as well as top mobile titles such as the Simpsons: Tapped Out at Electronic Arts and Disney Magic Kingdom at Gameloft. Additionally, their past expertise extends to helping engineer backend systems used by some of the biggest games in the industry such as EA Sports titles at Electronics Arts.

    Under the terms of the LOI, BlueLine will have a right of first offer for any talent-related game development projects from Caravan for five years following the closing of the acquisition. During this period, BlueLine can decide to take on any potential gaming-related collaboration with talent which would allow BlueLine to execute its vision of delivering unforgettable, interactive chart-topping experiences that connect fans with their favorite celebrities.

    The BlueLine team intends to leverage its experience in Artificial Intelligence (AI) in games and incorporate advancements in content generation to create ever expanding experiences. Following the acquisition, BlueLine will focus on the development of the Hollywood Sunshine project. This new game project, is expected to be a unique social gaming platform that features multiple celebrities and is driven by AI-generated content (AIGC). The Hollywood Sunshine project will be an engaging story-based role-playing game (RPG) set in an open world, available on both PC and mobile platforms. BlueLine aims to captivate users with real-time, instantaneous player-specific content generation, offering many hours of narrative-driven gameplay. Additonally, Caravan has agreed to bring at least three relevant star talents to participate in the game, assuming the acquisition is successfully completed.

    Xuezhu Wang, CEO and the Chairman of the Board of the Company, commented, "Completing this acquisition as envisioned would signify the beginning of an exciting new chapter for Paranovus Entertainment Technology Ltd. It will position us favorably as an AI-driven gaming and entertainment enterprise. The extensive expertise of BlueLine's seasoned team and their long-standing relationships with Caravan and CAA will bring tremendenous value to our Company. Furthermore, the potential synergies between BlueLine and 2Lab3, both sharing a similar focus on AI, will further contribute to our future growth."

    "Partnering with a company that supports and shares our vision and values presents a remarkable opportunity," stated Mike Teh Wang, CEO of BlueLine. "Our talented team is thrilled to join forces with PAVS after the close of the acqusition, leveraging our AI-powered technology and unique celebrity resources to develop and deliver an exclusive social gaming platform highlighting various celebrities."

    If successfully finalized, the acquisition of BlueLine will be the latest milestone for the Company, further demonstrating its new strategic focus on the burgeoning field of AI-powered pan-entertainment. In March 2023, PAVS acquired 2Lab3, a Los Angeles-based firm that initially focused on Web3 but has recently shifted its focus towards the development of AI-powered applications, marking the Company's first step into this emerging technology field.

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    4/2/26 8:45:19 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    3/25/26 9:13:48 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Paranovus Entertainment Technology Ltd.

    424B5 - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    3/25/26 2:10:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paranovus Entertainment Technology Limited Announces Pricing of $5 Million Registered Direct Offering At-The-Market Under NASDAQ Rules

    NEW YORK, March 24, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that it has entered into a definitive agreement with a single institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 14,285,715 Class A ordinary shares (or Class A ordinary share equivalents in lieu thereof) at a purchase price of $0.35 per share. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting placement agent commissions and other offering expenses. The offering is expected to close on or about March 25, 2026, subject to the satisfaction of customary clos

    3/24/26 3:09:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Xu George Yijian

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:50 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Guo Ling

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:24 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Lu David Sean

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/18/26 8:28:18 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care